



ASX ANNOUNCEMENT

2 June 2025

## **CARDIEX RECEIVES TGA APPROVAL FOR CONNEQT PULSE DEVICE**

Cardiex Limited (ASX: CDX) (the **Company**), is pleased to announce that its CONNEQT Pulse arterial health monitor has been approved by the Therapeutic Goods Administration (TGA) for use in Australia. The Pulse is now included in the Australian Register of Therapeutic Goods (ARTG), clearing the way for commercial activities in the Australian market.

The TGA approval follows the Company's prior clearance from the U.S. Food and Drug Administration (FDA).

The Pulse is a world-first clinical-grade vascular biometric monitoring device designed for use in both clinical and remote patient monitoring or at-home care settings. It enables the capture of a broad range of arterial health biomarkers, including central blood pressure and arterial stiffness, which are key indicators for cardiovascular risk and vascular health.

With TGA approval now in place, Cardiex will begin exploring commercialisation opportunities in Australia with an initial focus on pharmaceutical, research and clinician markets. These sectors represent early entry points for integration of the Pulse into specialist use cases across clinical trials and cardiovascular disease management care.

Cardiex CEO Craig Cooper commented:

*"TGA approval of the Pulse is another milestone for Cardiex as we expand our regulatory and commercial opportunities. This approval reflects our commitment to delivering advanced cardiovascular solutions to global healthcare markets. While the U.S. remains our primary focus at this stage, we're excited to begin laying the foundation for growth in Australia."*

**Approved by the Board of Directors and Released by the Company Secretary**

**- ENDS -**

For more information, please contact:

Investor Relations  
Rod Hinchcliffe  
rod.hinchcliffe@mcpartners.com.au

Media Relations  
Melissa Hamilton  
melissa.hamilton@mcpartners.com.au

### **About Cardiex**

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").